Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Breast Cancer Therapeutics Market Outlook 2025 - ResearchAndMarkets.com

May 3, 2019

DUBLIN--(BUSINESS WIRE)--May 3, 2019--The “Global Breast Cancer Therapeutics Market [(By Drug Type - HER2 Inhibitors, CDK4/6 Inhibitors & Aromatase Inhibitors; By Region - North America (The US), Europe (Germany) & Asia Pacific (Japan)] Outlook 2025” report has been added to ResearchAndMarkets.com’s offering.

The breast cancer therapeutics market has witnessed the advent of innovative novel therapies such as a combination of PARP inhibitors and CDK inhibitors. The advent of personalized breast cancer therapies is also expected to emerge as a game-changer in the industry. This report provides in-depth analysis of the current scenario, detailed market outlook of the global breast cancer therapeutics market overall as well as across various geographies. Regional analysis is done across major markets in North America, Europe, and Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market-specific growth opportunities in the global breast cancer therapeutics market.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Breast Cancer

3.1 Overview

3.1.1 Causes

3.1.2 Symptoms

3.1.3 Stages

3.2 Types

3.2.1 Hormone receptor (HR)-positive

3.2.2 Human epidermal growth factor receptor 2 (HER2)-positive

3.2.3 Triple-negative breast cancer (TNBC)

3.3 Diagnosis & Treatment

3.3.1 Diagnosis

3.3.2 Treatment

4. Market Analysis

4.1 Market Sizing (Actual & Forecasted)

4.2 Market Share Analysis

4.2.1 Market Share by Stage

4.2.2 Market Share by Type

4.2.3 Market Share by Region

5. Market Segmentation - Drug Type

5.1 HER2 Inhibitors

5.1.1 Overview

5.1.2 Market Sizing (Actual & Forecasted)

5.2 CDK4/6 Inhibitors

5.2.1 Overview

5.2.2 Market Sizing (Actual & Forecasted)

5.3 Aromatase Inhibitors

5.3.1 Overview

5.3.2 Market Sizing (Actual & Forecasted)

6. Regional Analysis

6.1 North America

6.1.1 Market Sizing (Actual & Forecasted)

6.1.2 The US Market Sizing (Actual & Forecasted) Market Share by Drug Types

6.2 Europe

6.2.1 Market Sizing (Actual & Forecasted)

6.2.2 Germany Market Sizing (Actual & Forecasted)

6.3 Asia Pacific

6.3.1 Market Sizing (Actual & Forecasted)

6.3.2 Market by Nations

6.3.3 Japan Market Sizing (Actual & Forecasted) Market Share by Drugs

7. Market Dynamics

7.1 Industry Trends & Developments

7.1.1 Mergers & Acquisitions

7.1.2 Emergence of Novel Therapies

7.1.3 Advent of Personalized & Targeted Therapies

7.2 Growth Drivers

7.2.1 Prevalence of Breast Cancer

7.2.2 Aging Population

7.2.3 Rapid Changes in Lifestyle

7.2.4 Increasing Public Awareness

7.3 Challenges

7.3.1 Patent Expirations of Blockbuster Drugs

7.3.2 Stringent Regulations

7.3.3 Lack of Awareness in LICs

7.3.4 High Prices of Therapies

8. Competitive Landscape

9. Company Profiles

  • Novartis International AG
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sanofi Pasteur SA
  • Pfizer Inc.
  • Astellas Pharma
  • Dendreon Corporation

For more information about this report visit https://www.researchandmarkets.com/r/iqfpye

View source version on businesswire.com:https://www.businesswire.com/news/home/20190503005339/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Breast Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/03/2019 11:00 AM/DISC: 05/03/2019 11:01 AM